Sidney Taurel
Sidney Taurel
Sidney Taurelis a Moroccan-born American businessman. He is the former Chairman and Chief Executive Officer of Eli Lilly and Company. He became chief executive officer in July 1998 and chairman of the board of directors on January 1, 1999. He was succeeded as chief executive officer by John C. Lechleiter on April 1, 2008. He now serves as an advisor at Moelis & Company...
commitment execution faster grow quarter rate reflect results sales strong
Our strong bottom-line results in the first quarter reflect the execution on our commitment to grow sales at a faster rate than our expenses.
building importance launching pipeline quarter strong
While the first quarter was a challenging quarter, it underscores the importance of building a strong pipeline and effectively launching new products,
broad built business challenges charlie company financial help internal judgment past reputation sound steer strong
During his tenure, Charlie used his broad business experiences and sound judgment to help steer the company through many challenges over the past decade. Through Charlie's leadership, we have built a world-class financial organization and strengthened Lilly's reputation for sound financial operations, transparency in our financial reporting, and strong internal controls.
ability add area bar behind bench dedication drive increase leadership leaves performance pivotal raise strong throughout transform valued
Charlie's leadership was pivotal in our drive to increase productivity in every part of Lilly. His ability to transform our organization and raise the bar in every area of performance has been invaluable. His dedication to leadership development is also evident. He leaves behind a strong bench of valued leaders who add value throughout the company.
bringing earnings half sales second stronger
As we expected, the second half of 2005 is bringing stronger sales and earnings growth,
expectation overall
I think there is an overall unreasonable expectation right now that there is such a thing as a risk-free drug.
earnings forward grow growth looking percent products share
Looking forward to 2006, our newer products should grow to about 24 percent of revenues and earnings per share should grow 8 to 11 percent, representing top-tier growth for large-cap pharmaceutical companies.
lives saving thousands
We're going to be saving hundreds of thousands of lives with this product,
completion confidence continued future high initiation level rapid reflect share
The rapid completion of the share repurchase program, coupled with the initiation of a new program, reflect the board's continued high level of confidence in the future of the company.
data erosion months nearly product prozac sales severe
With nearly two months of Prozac sales data available, the erosion in prescriptions is the most severe ever for a blockbuster product in our industry,
built class financial reputation sound
Through Charlie's leadership, we have built a world-class financial organization and strengthened Lilly's reputation for sound financial operations.
economy growing region resilient seeing seems
We are seeing a very resilient economy and one that seems to be growing in every part of the world. Just about every region is growing and it's very encouraging.
access affordable best care disaster ensure founders health nearly needing patients people survivors values whether
Whether they are patients needing access to affordable health care or survivors of a disaster, we do our best to ensure that people in need are not forgotten. Our founders established these values nearly 130 years ago, and we live by them today.
forward join leadership role senior vital
He is very well-prepared for the vital role he will play, and I look forward to having him join our senior leadership team.